PriceTargets.com logo

Merus - MRUS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $93.56
  • Forecasted Upside: -2.76%
  • Number of Analysts: 18
  • Breakdown:
  • 1 Sell Ratings
  • 14 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$96.22 As of 12/4/2025 05:00 PM ET
▲ +0.1 (0.10%)

This chart shows the closing price for MRUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRUS

Analyst Price Target is $93.56
▼ -2.76% Downside Potential
This price target is based on 18 analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $93.56, with a high forecast of $97.00 and a low forecast of $70.00. The average price target represents a -2.76% upside from the last price of $96.22.

This chart shows the closing price for MRUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 18 contributing investment analysts is to hold stock in Merus. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 2 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 14 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 14 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/31/2025BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$97.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/6/2025Leerink PartnersReiterated RatingOutperform ➝ Market Perform$95.00 ➝ $97.00
10/5/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
9/30/2025UBS GroupDowngradeBuy ➝ Neutral$72.00 ➝ $97.00
9/30/2025BMO Capital MarketsDowngradeOutperform ➝ Hold
9/30/2025BarclaysReiterated RatingOverweight ➝ Equal Weight$112.00 ➝ $97.00
9/30/2025BarclaysDowngradeOverweight ➝ Equal Weight$112.00 ➝ $97.00
9/30/2025GuggenheimReiterated RatingBuy ➝ Neutral$109.00 ➝ $97.00
9/30/2025Lifesci CapitalReiterated RatingOutperform ➝ Market Perform$97.00
9/29/2025HC WainwrightDowngradeBuy ➝ Neutral$135.00 ➝ $97.00
9/29/2025Canaccord Genuity GroupDowngradeBuy ➝ Hold$67.00 ➝ $97.00
9/29/2025William BlairDowngradeStrong-Buy ➝ Hold
9/29/2025Truist FinancialDowngradeBuy ➝ Hold$88.00 ➝ $97.00
9/29/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$95.00 ➝ $97.00
9/29/2025Needham & Company LLCDowngradeBuy ➝ Hold$96.00
9/29/2025Lifesci CapitalDowngradeStrong-Buy ➝ Hold
9/29/2025GuggenheimDowngradeStrong-Buy ➝ Hold
9/29/2025Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$95.00 ➝ $97.00
9/29/2025CitigroupDowngradeBuy ➝ Neutral$101.00 ➝ $97.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/17/2025BarclaysInitiated CoverageOverweight$112.00
9/16/2025BarclaysInitiated CoverageOverweight$112.00
8/25/2025Industrial Alliance SecuritiesSet Target$90.00
8/25/2025Alliance Global PartnersInitiated CoverageBuy$90.00
8/6/2025HC WainwrightUpgradeStrong-Buy
8/6/2025Needham & Company LLCLower TargetBuy ➝ Buy$97.00 ➝ $96.00
5/23/2025BMO Capital MarketsSet TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/8/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$91.00 ➝ $89.00
4/28/2025William BlairReiterated RatingOutperform
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$83.00 ➝ $83.00
3/28/2025GuggenheimReiterated RatingBuy ➝ Buy$109.00 ➝ $109.00
3/18/2025GuggenheimReiterated RatingBuy ➝ Buy$109.00 ➝ $109.00
3/10/2025Bank of AmericaLower TargetBuy ➝ Buy$73.00 ➝ $70.00
3/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
2/28/2025William BlairReiterated RatingOutperform
2/28/2025Needham & Company LLCLower TargetBuy ➝ Buy$85.00 ➝ $83.00
2/13/2025Piper SandlerInitiated CoverageOverweight$84.00
2/12/2025GuggenheimReiterated RatingBuy ➝ Buy
2/7/2025Wells Fargo & CompanyInitiated CoverageOverweight$91.00
12/9/2024CitigroupBoost TargetBuy ➝ Buy$89.00 ➝ $97.00
12/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
12/3/2024GuggenheimReiterated RatingBuy ➝ Buy$111.00 ➝ $109.00
12/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
12/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
11/21/2024The Goldman Sachs GroupInitiated CoverageBuy$73.00
11/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
11/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
11/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
10/24/2024UBS GroupInitiated CoverageBuy$72.00
10/1/2024GuggenheimBoost TargetBuy ➝ Buy$93.00 ➝ $111.00
8/5/2024Needham & Company LLCLower TargetBuy ➝ Buy$92.00 ➝ $85.00
7/29/2024Lifesci CapitalUpgradeStrong-Buy
7/25/2024Canaccord Genuity GroupUpgradeStrong-Buy
7/25/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$67.00 ➝ $67.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$92.00 ➝ $92.00
6/26/2024CitigroupBoost TargetBuy ➝ Buy$70.00 ➝ $93.00
6/25/2024Bank of AmericaReiterated RatingBuy ➝ Buy$76.00 ➝ $76.00
6/17/2024Stifel NicolausBoost TargetBuy ➝ Buy$90.00 ➝ $99.00
6/5/2024Bank of AmericaLower TargetBuy ➝ Buy$80.00 ➝ $76.00
6/4/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$54.00 ➝ $67.00
6/4/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$84.00 ➝ $91.00
6/4/2024Truist FinancialBoost TargetBuy ➝ Buy$69.00 ➝ $88.00
5/28/2024GuggenheimBoost TargetBuy ➝ Buy$57.00 ➝ $93.00
5/28/2024Stifel NicolausBoost TargetBuy ➝ Buy$65.00 ➝ $90.00
5/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
5/24/2024Bank of AmericaBoost TargetBuy ➝ Buy$52.00 ➝ $61.00
5/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00
4/22/2024William BlairReiterated RatingOutperform
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00
3/28/2024Truist FinancialInitiated CoverageBuy$69.00
3/4/2024Needham & Company LLCBoost TargetBuy ➝ Buy$42.00 ➝ $65.00
2/29/2024HC WainwrightBoost TargetBuy ➝ Buy$48.00 ➝ $65.00
2/29/2024Stifel NicolausBoost TargetBuy ➝ Buy$40.00 ➝ $65.00
2/29/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$49.00 ➝ $58.00
12/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00
11/28/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00
11/2/2023Canaccord Genuity GroupInitiated CoverageBuy$45.00
11/2/2023Canaccord Genuity GroupInitiated CoverageBuy$45.00
10/24/2023Stifel NicolausLower TargetBuy ➝ Buy$45.00 ➝ $40.00
9/14/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
8/21/2023TD CowenInitiated CoverageOutperform
8/10/2023CitigroupLower TargetBuy ➝ Buy$48.00 ➝ $46.00
8/8/2023GuggenheimBoost TargetBuy ➝ Buy$46.00 ➝ $48.00
8/8/2023Stifel NicolausBoost TargetBuy ➝ Buy$44.00 ➝ $45.00
8/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$48.00
7/24/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
6/30/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00
5/18/2023CitigroupBoost Target$47.00 ➝ $48.00
5/5/2023HC WainwrightBoost Target$40.00 ➝ $48.00
4/18/2023Stifel NicolausBoost TargetBuy$34.00 ➝ $44.00
4/18/2023BMO Capital MarketsBoost Target$47.00 ➝ $49.00
4/17/2023SVB SecuritiesBoost TargetOutperform$35.00 ➝ $48.00
4/17/2023GuggenheimBoost TargetBuy$38.00 ➝ $45.00
4/17/2023CitigroupBoost TargetBuy$38.00 ➝ $47.00
4/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$35.00
4/14/2023Needham & Company LLCReiterated RatingBuy$33.00
4/6/2023Needham & Company LLCReiterated RatingBuy$33.00
4/5/2023CitigroupBoost TargetBuy$30.00 ➝ $38.00
3/16/2023BMO Capital MarketsBoost TargetOutperform$46.00 ➝ $47.00
3/1/2023Needham & Company LLCLower TargetBuy$35.00 ➝ $33.00
3/1/2023EF Hutton Acquisition Co. IReiterated RatingBuy$35.00
3/1/2023HC WainwrightBoost TargetBuy$39.00 ➝ $40.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$35.00
11/16/2022CitigroupLower TargetBuy$34.00 ➝ $30.00
11/4/2022Leerink PartnersLower TargetOutperform$39.00 ➝ $35.00
11/4/2022Needham & Company LLCLower TargetBuy$40.00 ➝ $28.00
11/4/2022HC WainwrightLower TargetBuy$45.00 ➝ $39.00
10/13/2022Leerink PartnersBoost TargetOutperform$33.00 ➝ $39.00
8/17/2022CitigroupLower TargetBuy$37.00 ➝ $34.00
8/2/2022Stifel NicolausInitiated CoverageBuy$38.00
7/18/2022GuggenheimBoost TargetBuy$44.00 ➝ $46.00
5/19/2022CitigroupLower TargetBuy$38.00 ➝ $37.00
5/10/2022HC WainwrightReiterated RatingBuy
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$45.00
2/10/2022Needham & Company LLCInitiated CoverageBuy$45.00
11/12/2021HC WainwrightBoost TargetBuy$30.00 ➝ $45.00
11/3/2021Royal Bank Of CanadaBoost TargetSector Perform$21.00 ➝ $33.00
10/11/2021CitigroupBoost TargetBuy$31.00 ➝ $38.00
10/8/2021Leerink PartnersBoost TargetOutperform$33.00 ➝ $45.00
10/7/2021Roth CapitalBoost TargetBuy$32.00 ➝ $40.00
8/9/2021HC WainwrightReiterated RatingBuy$30.00
6/11/2021William BlairReiterated RatingBuy
6/7/2021CitigroupUpgradeNeutral ➝ Buy
5/9/2021Leerink PartnersReiterated RatingBuy$33.00
4/8/2021William BlairInitiated CoverageOutperform
3/17/2021Royal Bank Of CanadaBoost TargetSector Perform$15.00 ➝ $21.00
3/17/2021HC WainwrightBoost TargetBuy$23.00 ➝ $30.00
3/16/2021Leerink PartnersInitiated CoverageOutperform$33.00
1/19/2021Roth CapitalBoost Target$19.00 ➝ $32.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.18 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 35 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 45 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 15 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 20 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 29 very positive mentions
  • 29 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 8 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
Mentions as of
11/4/2025
  • 18 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 18 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Merus logo
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $96.22
Low: $96.01
High: $96.27

50 Day Range

MA: $94.62
Low: $68.89
High: $96.22

52 Week Range

Now: $96.22
Low: $33.19
High: $96.28

Volume

1,425,949 shs

Average Volume

1,348,147 shs

Market Capitalization

$7.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Merus?

The following Wall Street analysts have issued research reports on Merus in the last twelve months: Alliance Global Partners, Bank of America Corporation, Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Citigroup Inc., Guggenheim, HC Wainwright, Industrial Alliance Securities, Leerink Partners, Leerink Partnrs, Lifesci Capital, Needham & Company LLC, Piper Sandler, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for MRUS.

What is the current price target for Merus?

0 Wall Street analysts have set twelve-month price targets for Merus in the last year. Their average twelve-month price target is $93.56, suggesting a possible downside of 2.8%. UBS Group AG has the highest price target set, predicting MRUS will reach $97.00 in the next twelve months. Bank of America Corporation has the lowest price target set, forecasting a price of $70.00 for Merus in the next year.
View the latest price targets for MRUS.

What is the current consensus analyst rating for Merus?

Merus currently has 1 sell rating, 14 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MRUS, but not buy more shares or sell existing shares.
View the latest ratings for MRUS.

What other companies compete with Merus?

Other companies that are similar to Merus include BioNTech, Genmab A/S, Revolution Medicines, Roivant Sciences and BridgeBio Pharma. Learn More about companies similar to Merus.

How do I contact Merus' investor relations team?

Merus' physical mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company's listed phone number is (130) 253-8800 and its investor relations email address is [email protected]. The official website for Merus is www.merus.nl. Learn More about contacing Merus investor relations.